Phagos announces a 30 million dollars Series A funding round, co-led by CapAgro, Hoxton Ventures, CapHorn and Demeter, with participation from Acurio Ventures, Citizen Capital, Entrepreneurs First, Founders Capital, and Station F.
This financing aims to accelerate the deployment of veterinary phage therapy in the field, develop the next generation of its patented AI technology for phage discovery, and drive the company’s growth globally (Europe, Asia, and the Americas).
Founded in 2021 by Alexandros Pantalis and Dr. Adèle James, Phagos has developed a groundbreaking phage therapy process, a natural alternative to antibiotics, to fight
bacterial diseases.
Bacterial diseases already rank as the world’s second leading cause of human mortality, one of the main causes of animal deaths, and generate massive losses in food waste.
Antimicrobial resistance causes millions of deaths every year and could cost the global economy up to $100 trillion by 2050. In livestock, one in three antibiotics is no longer effective, three times more than in the year 2000.
To meet this challenge, Phagos combines microbiology and artificial intelligence within a unique platform capable of designing ultra-precise, personalized treatments to put an end to bacterial diseases.
Its first application focuses on animal health, a sector heavily impacted by bacterial infections (Salmonella, E. coli…) and the growing limitations of antibiotics, with the ultimate ambition of extending phage therapy to human health.
